Find Clinical Trial
Efficacy of agomelatine (25 to 50 mg/day) given orally on quality of remission in elderly depressed patients, after a 12-week treatment period.A randomised, double-blind, flexible-dose international multicentre study with parallel groups versus paroxetine (20 to 30 mg/day).Twelve-week treatment plus optional continuation for 12 weeks.
← Back
| Study Phase |
Phase 3 |
| Therapeutic Area |
Neuropsychiatric Diseases |
| Indication | Major Depressive Disorder |
| Sponsor | Institut de Recherches Internationales Servier (I.R.I.S) |
| Active substance/ Medical device |
AGOMELATINE, |
| Active Substance Code | S020098 |
| Protocol Code | CL3-20098-048 |
| EudraCT Code | 2005-002388-95 |
| ISRCTN Code | ISRCTN68222771 |
Documents and links
| Results summary | READ MORE  |
| Scientific publication | READ MORE |
Servier Glossary of Terms
To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.
© 2024 LES LABORATOIRES SERVIER, an incorporated company of Servier.
All Rights Reserved. Servier does not sell its products over the Internet.
All Rights Reserved. Servier does not sell its products over the Internet.
Accessibility
